Atomwise AI

Atomwise AI

Atomwise AI leverages its proprietary AtomNet® platform to accelerate small-molecule drug discovery with deep convolutional neural networks, enabling efficient virtual screening and optimization of a library of over 16 billion compounds.
Rating:
5
Visit Website
AI drug discoveryAtomNet platformvirtual screening of compoundssmall-molecule drug designdeep learning in drug discoverytarget binding prediction

Features of Atomwise AI

Based on the AtomNet® deep convolutional neural network, it accurately predicts interactions between small molecules and protein targets.
Capable of efficiently screening a virtual library containing more than 16 billion compounds, shortening the early discovery timeline from years to weeks.
Able to tackle hard-to-drug targets with limited structural data, expanding the frontier of drug discovery.
Validated through the AIMS program to achieve about 74% screening accuracy, with continued discovery of structurally novel compounds.
Supports the full early-stage drug discovery workflow from virtual screening to lead optimization and drug repurposing.

Use Cases of Atomwise AI

Pharmaceutical companies use it during the early drug discovery stage to rapidly screen large chemical libraries for promising lead compounds.
Research institutions use it to design new drug molecules for targets that lack crystal structures or are difficult for traditional methods to handle.
Biotech companies seek AI solutions to reduce R&D costs and accelerate programs, as an alternative to traditional experimental high-throughput screening.
Academic laboratories use the AIMS program to conduct large-scale, low-cost virtual screening validation studies for specific disease targets.
When responding to emerging public health events (e.g., Ebola), there is a need to identify potential therapeutic candidate molecules in an extremely short timeframe.

FAQ about Atomwise AI

QWhat is Atomwise AI?

Atomwise AI is an AI-powered biopharma company focused on accelerating small-molecule drug discovery and design using artificial intelligence, especially deep convolutional neural networks, with its core being the proprietary AtomNet® platform.

QWhat can the AtomNet platform mainly do?

The AtomNet platform can simulate molecular structures and predict the binding affinity between small molecules and protein targets, enabling efficient and accurate screening of virtual libraries containing hundreds of billions of compounds to identify promising drug candidate molecules.

QWhat are the advantages of using Atomwise AI for drug discovery?

The main advantages are dramatically improved screening efficiency and breadth, shortening the traditional multi-year early discovery timeline to weeks, exploring a broader chemical space, addressing difficult-to-drug targets, and reducing R&D costs.

QIn which disease areas is Atomwise AI technology applied?

Its technology has been applied across oncology, neurological disorders, rare diseases, immune and inflammatory diseases, among others, and it collaborates with multiple pharmaceutical companies and academic institutions on related target research.

QHow accurate is Atomwise AI's virtual screening?

According to validation data from its AIMS program, the AtomNet platform can screen targets with about 74% accuracy and continually discovers structurally novel compounds, serving as a viable alternative to traditional experimental screening.

QHow to collaborate with Atomwise AI?

Atomwise AI has established broad collaborations with major pharmaceutical and biotech companies and leading research universities worldwide; academic institutions can apply for targeted virtual screening studies through the AIMS program.